| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 6.1K | 6.8% | 16.9% |
| Total Income | 6.2K | 7.4% | 17.5% |
| Expenditure | 4.5K | 6.2% | 11.8% |
| PBT | 1.7K | 12.1% | 32.8% |
| Net Profit | 1.2K | 18.6% | 34.6% |
| OPM | 32.36% | 0.59pp | 14.33pp |
| NPM | 19.87% | 2.73pp | 2.95pp |
| EPS | 12.51 | 14.2% | 38.2% |
Zydus Lifesciences Announces Q2 & H1 FY26 Financial Results: Revenue Up 17% & 11% Respectively
06 Nov 2025 · 6 Nov 2025, 01:16 pm
Summary
Zydus Lifesciences Ltd. announced its unaudited consolidated financial results for the quarter and half year ended September 30, 2025. The company reported a 17% YoY increase in revenue from operations for Q2 FY26, and an 11% YoY increase for H1 FY26. EBITDA for Q2 FY26 was up 38% YoY, and EBITDA margin stood at 32.9%. Net Profit for the quarter was up 38% YoY. Capex (organic) for the quarter was Rs. 4,911 mn. For H1 FY26, EBITDA was up 16% YoY, and Net Profit was up 17% YoY. Capex (organic) for the half year was Rs. 8,931 mn. The Net Debt to Equity ratio as on 30 September, 2025 was 0.09x, and Net Debt to EBITDA stood at 0.3x at the end of September, 2025.
Key Highlights
- 1
Revenue from operations at Rs. 61,232 mn for Q2 FY26, up 17% over last year
- 2
R&D investments for the quarter stood at Rs. 4,820 mn (7.9% of revenues)
- 3
EBITDA for the quarter was Rs. 20,158 mn, up 38% YoY
- 4
Net Profit for the quarter was Rs. 12,586 mn, up 38% YoY
- 5
Capex (organic) for the quarter was Rs. 4,911 mn
- 6
Revenue from operations at Rs. 126,969 mn for H1 FY26, up 11% over last year
- 7
R&D investments stood at Rs. 9,676 mn (7.6% of revenues) for H1 FY26
- 8
EBITDA was Rs. 41,043 mn, up 16% YoY for H1 FY26
- 9
Net Profit was Rs. 27,254 mn, up 17% YoY for H1 FY26
- 10
Capex (organic) for the half year was Rs. 8,931 mn
- 11
Net Debt to Equity ratio as on 30 September, 2025 was 0.09x
- 12
Net Debt to EBITDA stood at 0.3x at the end of September, 2025
Management Comments
Dr. Sharvil Patel
Managing Director - Zydus Lifesciences Limited
Our strong performance this quarter reaffirms the power of our diversified business model and our execution capabilities across geographies and verticals. We delivered robust revenue growth and industry-leading profitability, aided by consistent outperformance in our US and India formulations businesses, sustained high growth in International Markets as well as strategic acquisitions in Wellness and MedTech. These results reflect our commitment to sustainable growth and global expansion, anchored in quality, compliance, and patient-centric innovation.
Informational and educational content only. Not investment advice.